Global Glycomic Market Revenue Grows at a CAGR of 13.85%

Introduction

Straits Research released its highly anticipated report, “Global Glycomics Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 2.12 billion in 2025 and is projected to expand to USD 6.79 billion by 2034, registering a compound annual growth rate (CAGR) of 13.85%.

Market Dynamics

The global glycomics market is witnessing substantial growth as the life sciences sector increasingly emphasizes the importance of glycans and glycosylation in biological processes, disease mechanisms, and therapeutic development. A major driver of market growth is the rising demand for glycomics technologies and analytical solutions in biologics and therapeutic development. Pharmaceutical and biotechnology companies rely heavily on glycan profiling and characterization tools to ensure the structural integrity, safety, and efficacy of complex therapeutic molecules. This demand is further fueled by the increasing focus on personalized and targeted treatments, where glycan biomarkers are used to tailor clinical interventions and enhance patient outcomes, particularly in oncology, immunology, and chronic disease research.

Despite strong market growth, a key restraint lies in the high cost and technical complexity of glycomics research infrastructure. Advanced analytical platforms such as high-resolution mass spectrometry, high-performance liquid chromatography, and glycan microarrays require substantial capital investment, specialized expertise, and ongoing operational expenses. These factors create barriers for smaller research institutions and emerging markets, slowing the widespread adoption of glycomics technologies and limiting market penetration outside well-funded academic and industrial laboratories.

On the other hand, the market presents major opportunities through the development of glycan-based diagnostic assays and integration with multi-omics approaches. As healthcare systems globally shift toward precision diagnostics and early disease detection, glycan signatures offer unique specificity and the potential for non-invasive testing. Investment in glycomics platforms that integrate genomics, proteomics, and glycan data unlocks deeper biological insights, enabling earlier detection of diseases, improved monitoring of therapeutic responses, and accelerated biomarker discovery.

Market Highlights

• Product: The enzymes segment is expected to register the fastest CAGR of 14.31% during the forecast period.
• Application: The drug discovery & development segment dominated the market with a revenue share of 46.02% in 2025.
• End User: The biopharmaceutical companies segment is estimated to register the fastest CAGR of 15.08%.
• Regional Insights: North America dominated the market, accounting for 37.41% share in 2025, owing to expanding applications of glycomics across drug discovery and biologics.

Competitive Players

1. Agilent Technologies Inc.
2. Asparia Glycomics SL
3. Bruker Corporation
4. Danaher
5. Dextra Laboratories
6. Genovis AB
7. GlycoSeLect Ltd.
8. Lectenz Bio
9. Ludger Ltd.
10. Merck KGaA
11. New England Biolabs
12. PerkinElmer Inc.
13. Promega Corporation
14. RayBiotech Life Inc.
15. Shimadzu Corporation
16. Takara Bio Inc.
17. Thermo Fisher Scientific Inc.
18. Waters Corporation
19. Others

Recent Developments

October 2025: GlycoNet and the Center for Cooperative Research in Biosciences agreed to deepen their collaboration in glycomics, the study of complex sugars that coat our cells and play vital roles in biology, from infection to immunity.

Segmentation

1. By Product (2026-2034)
   1. Enzymes
      1. Glycosidases
      2. Neuraminidases
      3. Glycosyltransferases
      4. Sialyltransferases
      5. Others
   2. Kits & Reagents
   3. Instruments
      1. Mass Spectrometers
      2. HPLC
      3. MALDI-TOF
      4. Microarray & Chip-Based Platforms
      5. Others
2. By Application (2026-2034)
   1. Drug Discovery & Development
   2. Diagnostics
   3. Others
3. By End User (2026-2034)
   1. Pharmaceutical & Biotechnology Companies
   2. Biopharmaceutical Companies
   3. Contract Research Organizations
   4. Academic & Research Institutes
   5. Others